Skip to main content
Premium Trial:

Request an Annual Quote

Peter O Hanley, Ray Cummings, and Denis Burger


AVI BioPharma announced this week that it has expanded its management team with the addition of two new vice presidents.

The company said that it has named Peter O’Hanley as its senior vice president of clinical development and regulatory affairs, and Ray Cummings as vice president of business development.

According to AVI, O’Hanley was previously vice president of clinical development at Maxygen, before which he was CSO of Preventis. He has also served as vice president and CSO for the anti-infective therapeutic and immunology therapeutic groups at Quintiles, said AVI.

O’Hanley received a PhD and MD from the Medical University of South Carolina, and received his master’s degree in public health from the University of California, Berkeley,

AVI added. AVI said that Cummings was most recently the founder and president of Cummings Consulting. Before his work at this firm, he served as vice president of business development at Aradigm. Prior to this, he was vice president of business development at Celtrix Pharmaceuticals.

AVI said that Cummings holds a master’s degree in business administration from the University of California, Berkeley and an MS in biochemistry and molecular biology from Harvard University.

“Peter and Ray have impressive backgrounds, including negotiating large partnership agreements, designing and implementing global cancer and infectious disease clinical trials, and managing regulatory affairs,” Denis Burger, CEO of AVI, said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.